Drug Study of Fracture

DRUG STUDY NAME OF DRUG Cefuroxime ORDERED DOSE MECHANISM OF ACTION INDICA TION -For skin or skin structure
infections, bone and joint infection. -perioperative prevention

CONTRAINDICA TION
ADVERSE REACTIONS
NURSING RESPONSIBILITIES -Assess patients infection before therapy and regularly thereafter. -Be alert for adverse reactions and drug interactions -for oral, instruct patient to take drug exactly as prescribed , even after he feels better -Before giving first dose, ask patient about previous reactions to cephalosporins.
Penicillin potassium
Patients CNS: Dizziness , headache, hypersensitive to malaise, paresthesia drug or other GI: abdominal cramps, anal cephalosporins pruritus, anorexia, diarrhea, dyspepsia, nausea GU: Candidiasis, pruritus Hematologic: eosinophilia, haemolytic anemia, thrombocytopenia, transient neutropenia Respiratory: Dyspnea Skin: Erythematous and maculopapular rashes, urticaria G 2.5 mil u Kills susceptible For moderate Patients CNS: Coma, neuropathy, seizures o hypersensitive to CV: Thrombophlebitis IV q6 bacteria to severe the drug or other Hematologic: Hemolytic anemia, infections penicillins leukopenia Metabolic: severe potassium poisoning
600 mg IV Hinders or kills q8o susceptible bacteria, including many gram- positive organisms and enteric gramnegative bacilli.
Clindamycin(D alacin C)
10 ml q8o Kills susceptible Infection per orem bacteria caused by specific microorganism
Patients hypersensitive to drug or lincomycin -use cautiously in patients with renal or hepatic disease, asthma, history of
CV: Thrombophlebitis EENT: Pharyngitis GI: Abdominal pain, anorexia, constipation, flatulence, vomiting GU: UTI Hematologic: eosinophilia,
Assess patients infection before starting therapy and regularly thereafter to monitor drugs effectiveness - Assess renal, cardiac and vascular conditions with physical exams and laboratory testing before start of therapy -Tell patient to report if rash, fever, or chills develop - Assess patients infection before starting therapy and regularly thereafter to monitor drugs effectiveness - Instruct patient to report diarrhea and to avoid self- treatment because of the risk of life- threatening pseudomembranous
Ibuprofen
GI disease or transient leukopenia significant allergies. Skin: maculopapular rash , urticaria o 7.5ml q6 Relieves pain , -mild to -patients CNS: Aseptic meningitis, for 2 days fever, and moderate pain hypersensitive to the cognitive dysfunction, dizziness , drug or any of its drowsiness, headache per orem inflammation components and in CV: Edema, heart failure, those with nasal peripheral edema polyps, angioedema EENT: Tinnitus, visual and bronchospastic disturbances reaction to aspirin or GI: Epigastric distress, nausea, other NSAIDS occult blood -Use cautiously in GU: Reversible renal failure patients with GI Hematologic: Agranulocytosis, disorders, history of anemia, aplastic anemia, peptic ulcer disease, leukopenia hepatic or renal disease, cardiac Respiratory: Bronchospasm Skin: Pruritus , rash decompensation,
colitis - Tell patient receiving drug IV to report discomfort at infusion site - Assess patients underlying condition before starting therapy - Evaluate patient for relief from pain, fever or inflammation. - Check renal and hepatic function periodically - Give with meals or milk to reduce adverse GI reactions - Warn patient that using drug with aspirin, alcohol or corticosteroids may increase the risk of adverse GI reactions - Teach patient to recognize and report signs and symptoms of GI bleeding such as blood on the stool
Amikacin sulphate
500 mg IV Kills susceptible Q 12O bacteria and many aerobic gram negative organisms.
Infections caused by specific microorganism
hypertension Patients hypersensitive to drug or other aminoglycosides -Use cautiously in patients with impaired renal failure or neuromuscular disorders
CNS: headache, neuromuscular blockade EENT: Ototoxicity GU: Nephrotoxicity Hepatic: Hepatic necrosis
Assess patients infection, hearing, weight, and renal function test values before therapy and regularly therafter - Watch for signs of ototoxicity, including tinnitus , vertigo , hearing loss - Monitor amikacin level. Obtain blood for peak amikacin level 1 hour after I.M. injection - Tell patient to report changes in hearing or urine appearance or elimination pattern - Emphasize importance of drinking 2L of fluid daily, unless contraindicated
Ketorolac Tromethamine
15 mg IV Relieves pain Short term -Patients o q6 and management of hypersensitive to the drug or any of its inflammation pain component; in those with a history of of nasal polyps, angioedema, bronchospastic reactivity or allergic reactions to aspirin or other NSAIDS, in those with advanced renal impairment. -use cautiously in patients in the perioperative period and in patients with hepatic or renal impairment.
CNS: dizziness, drowsiness, headache, insomnia, syncope CV: Edema, hypertension, palpitations EENT: corneal edema, keratitis GI: Diarrhea, dyspepsia, GI pain, nausea GU: Hematuria, polyuria Hematologic: anemia, eosinophilia Skin: Sweating
Assess patients pain before and after drug therapy - -Be alert for adverse reactions and drug interactions - Teach patient to recognize and immediately report signs and symptoms of GI Bleeding such as occult blood - Advise patient to report persistent or worsening pain.

Drug Study of Fracture

Uploaded by

Copyright:

Available Formats

Drug Study of Fracture

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Drug Study of Fracture

Uploaded by

Copyright:

Available Formats

DRUG STUDY NAME OF DRUG Cefuroxime ORDERED DOSE MECHANISM OF ACTION INDICA TION -For skin or skin structure

infections, bone and joint infection. -perioperative prevention

Infections caused by specific microorganism

You might also like

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.